Li Guo-li, Fan Chao-gang, Bao Yang, Jiang Jun, Li Ning, Li Jie-shou
Research Institute of General Surgery, Nanjing General Hospital of Nanjing Military Command, Nanjing 210002, China.
Zhonghua Wai Ke Za Zhi. 2009 Aug 1;47(15):1171-4.
To observe the therapeutic response of advanced gastric cancer with severe lymph nodes metastasis to FLEEOX regimen neoadjuvant chemotherapy that combined arterial and venous administration.
Neoadjuvant chemotherapy was administered to 32 cases of gastric cancer with advanced abdominal lymph nodes metastases from January 2007 to October 2008. Of the 32 patients, 28 had severe local lymph nodes metastasis, such as No.3, 7, 9, 12 lymph nodes metastasis, one patient had No.16 lymph nodes metastasis, and the other 3 patients had both regional and No.16 lymph nodes metastasis under CT scan. Neoadjuvant chemotherapy was administered as follows: 5-Fu 370 mg/m(2), intravenous drip, day 1 - 5; Leukovorin 120 mg, intravenous drip, day 1 - 5; oxaliplatin 150 mg/m(2), epirubicin 30 mg/m(2) and epotoside 70 mg/m(2), intravascular infusion through arteria gastrica sinistra, day 6 and 20. The protocol was repeated every five weeks for two or three courses. After 2 or 3 cycles of chemotherapy, abdominal CT was taken to evaluate the radiological therapeutic response and calculate the reductive rate of the tumor.
The general conditions and symptoms was improved significantly in all the patients. Four cases got complete response (CR), 24 got partial response (PR) and 4 got no change under CT scan. For the 32 case, the radiological response rate (CR + PR) was 87.5%(28/32). Thirty patients underwent subtotal or total gastrectomy, even combined organ resection, with D2 or D2 + alpha lymphadenectomy.
The FLEEOX regimen which combines arterial and venous administration carries a satisfactory therapeutic effect in advanced gastric cancer with severe lymph nodes metastasis. The combined routes of drug administration may improve the effects of neoadjuvant chemotherapy in stomach cancer.
观察氟尿嘧啶(5-Fu)、亚叶酸钙(LV)、奥沙利铂、表柔比星联合依托泊苷动脉与静脉联合给药的FLEEOX方案新辅助化疗对伴有严重淋巴结转移的进展期胃癌的治疗反应。
2007年1月至2008年10月,对32例伴有晚期腹部淋巴结转移的胃癌患者进行新辅助化疗。32例患者中,28例存在严重局部淋巴结转移,如第3、7、9、12组淋巴结转移,1例患者存在第16组淋巴结转移,另外3例患者在CT扫描下既有区域淋巴结转移又有第16组淋巴结转移。新辅助化疗方案如下:5-Fu 370mg/m²,静脉滴注,第1 - 5天;亚叶酸钙120mg,静脉滴注,第1 - 5天;奥沙利铂150mg/m²、表柔比星30mg/m²及依托泊苷70mg/m²,经胃左动脉血管内灌注,第6天和第20天。每5周重复该方案,共进行2或3个疗程。化疗2或3周期后,行腹部CT检查以评估影像学治疗反应并计算肿瘤缩小率。
所有患者的一般状况和症状均有明显改善。CT扫描显示4例完全缓解(CR),24例部分缓解(PR),4例无变化。32例患者的影像学反应率(CR + PR)为87.5%(28/32)。30例患者接受了胃大部切除术或全胃切除术,甚至联合器官切除,并进行了D2或D2 + α淋巴结清扫术。
动脉与静脉联合给药的FLEEOX方案对伴有严重淋巴结转移的进展期胃癌具有满意的治疗效果。联合给药途径可能提高胃癌新辅助化疗的效果。